e23546 Background: Despite intensive treatment, the chance of cure for patients with
recurrent rhabdomyosarcoma (RMS) is very low, highlighting the need for an improved …

The genomic spectrum of rhabdomyosarcoma (RMS) progression from primary to relapse is
not fully understood. In this pilot study, we explore the sensitivity of various targeted and …

Purpose: Increased availability of next-generation sequencing has allowed for the genomic
characterization of a variety of pediatric tumors, although genomic determinants of response …

Purpose Evaluation of primary tumor-, treatment-, and patient-related factors predicting
relapse pattern, risk, and survival after relapse with the aim to design a risk-adapted, tumor …

Pleomorphic rhabdomyosarcoma (PRMS) is a rare and aggressive adult sarcoma with a
median overall survival of less than 2 years. Most PRMS do not respond to conventional …

Background: Rhabdomyosarcoma (RMS) is the most prevalent soft tissue sarcoma in
children and adolescents. It is divided in two major histological subtypes, being the Alveolar …

Introduction: A classification of rhabdomyosarcoma (RMS) with prognostic relevance has
primarily relied on clinical features and histologic classification as either embryonal or …

Pleomorphic rhabdomyosarcoma (PRMS) is a rare and highly aggressive sarcoma,
occurring mostly in the deep soft tissues of middle‐aged adults and showing a variable …

Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific
precision therapies. Druggable driver oncogenes, identified by molecular analyses, are …

Purpose We investigated whether tumors from diagnostic biopsies of primary
rhabdomyosarcoma (RMS) contain relevant prognostic information in the form of gene …